Cargando…

CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies

BACKGROUND AND OBJECTIVE: Severe attacks of myelin oligodendrocyte glycoprotein (MOG) antibody–associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory support, but data on episodes are limited, particularly for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao-Fleming, Hannah H., Valencia Sanchez, Cristina, Sechi, Elia, Inbarasu, Jery, Wijdicks, Eelco F., Pittock, Sean J., Chen, John J., Wingerchuk, Dean M., Weinshenker, Brian G., Lopez-Chiriboga, Sebastian, Dubey, Divyanshu, Tillema, Jan-Mendelt, Toledano, Michel, Yadav, Hemang, Flanagan, Eoin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480400/
https://www.ncbi.nlm.nih.gov/pubmed/34389648
http://dx.doi.org/10.1212/WNL.0000000000012599
_version_ 1784576457800941568
author Zhao-Fleming, Hannah H.
Valencia Sanchez, Cristina
Sechi, Elia
Inbarasu, Jery
Wijdicks, Eelco F.
Pittock, Sean J.
Chen, John J.
Wingerchuk, Dean M.
Weinshenker, Brian G.
Lopez-Chiriboga, Sebastian
Dubey, Divyanshu
Tillema, Jan-Mendelt
Toledano, Michel
Yadav, Hemang
Flanagan, Eoin P.
author_facet Zhao-Fleming, Hannah H.
Valencia Sanchez, Cristina
Sechi, Elia
Inbarasu, Jery
Wijdicks, Eelco F.
Pittock, Sean J.
Chen, John J.
Wingerchuk, Dean M.
Weinshenker, Brian G.
Lopez-Chiriboga, Sebastian
Dubey, Divyanshu
Tillema, Jan-Mendelt
Toledano, Michel
Yadav, Hemang
Flanagan, Eoin P.
author_sort Zhao-Fleming, Hannah H.
collection PubMed
description BACKGROUND AND OBJECTIVE: Severe attacks of myelin oligodendrocyte glycoprotein (MOG) antibody–associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory support, but data on episodes are limited, particularly for MOGAD. We sought to compare the frequency, characteristics, and outcomes of MOGAD and AQP4-NMOSD attacks requiring ventilatory support. METHODS: This retrospective descriptive study identified Mayo Clinic patients (January 1, 1996–December 1, 2020) with MOGAD or AQP4-NMOSD and an attack requiring noninvasive or invasive ventilation at Mayo Clinic or an outside facility by searching for relevant terms in their electronic medical record. Inclusion criteria were (1) attack-related requirement for noninvasive (bilevel positive airway pressure or continuous positive airway pressure) or invasive respiratory support (mechanical ventilation); (2) MOG or AQP4 antibody positivity with fulfillment of MOGAD and AQP4-NMOSD clinical diagnostic criteria, respectively; and (3) sufficient clinical details. We collected data on demographics, comorbid conditions, indication for and duration of respiratory support, MRI findings, treatments, and outcomes. The races of those with attacks requiring respiratory support were compared to those without such attacks in MOGAD and AQP4-NMOSD. RESULTS: Attacks requiring ventilatory support were similarly rare in patients with MOGAD (8 of 279, 2.9%) and AQP4-NMOSD (11 of 503 [2.2%]) (p = 0.63). The age at attack (median years [range]) (MOGAD 31.5 [5–47] vs AQP4-NMOSD 43 [14–65]; p = 0.01) and percentage of female sex (MOGAD 3 of 8 [38%] vs AQP4-NMOSD 10 of 11 [91%]; p = 0.04) differed. The reasons for ventilation differed between MOGAD (inability to protect airway from seizure, encephalitis or encephalomyelitis with attacks of acute disseminated encephalomyelitis 5 [62.5%] or unilateral cortical encephalitis 3 [37.5%]) and AQP4-NMOSD (inability to protect airway from cervical myelitis 9 [82%], rhombencephalitis 1 [9%], or combinations of both 1 [9%]). Median ventilation duration for MOGAD was 2 days (range 1–7 days) vs 19 days (range 6–330 days) for AQP4-NMOSD (p = 0.01). All patients with MOGAD recovered, but 2 of 11 (18%) patients with AQP4-NMOSD died of the attack. For AQP4-NMOSD, Black race was overrepresented for attacks requiring ventilatory support vs those without these episodes (5 of 11 [45%] vs 88 of 457 [19%]; p = 0.045). DISCUSSION: Ventilatory support is rarely required for MOGAD and AQP4-NMOSD attacks, and the indications differ. Compared to MOGAD, these attacks in AQP4-NMOSD may have higher morbidity and mortality, and those of Black race were more predisposed, which we suspect may relate to socially mediated health inequality.
format Online
Article
Text
id pubmed-8480400
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-84804002021-09-30 CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies Zhao-Fleming, Hannah H. Valencia Sanchez, Cristina Sechi, Elia Inbarasu, Jery Wijdicks, Eelco F. Pittock, Sean J. Chen, John J. Wingerchuk, Dean M. Weinshenker, Brian G. Lopez-Chiriboga, Sebastian Dubey, Divyanshu Tillema, Jan-Mendelt Toledano, Michel Yadav, Hemang Flanagan, Eoin P. Neurology Research Article BACKGROUND AND OBJECTIVE: Severe attacks of myelin oligodendrocyte glycoprotein (MOG) antibody–associated disorder (MOGAD) and aquaporin-4 (AQP4) antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) may require ventilatory support, but data on episodes are limited, particularly for MOGAD. We sought to compare the frequency, characteristics, and outcomes of MOGAD and AQP4-NMOSD attacks requiring ventilatory support. METHODS: This retrospective descriptive study identified Mayo Clinic patients (January 1, 1996–December 1, 2020) with MOGAD or AQP4-NMOSD and an attack requiring noninvasive or invasive ventilation at Mayo Clinic or an outside facility by searching for relevant terms in their electronic medical record. Inclusion criteria were (1) attack-related requirement for noninvasive (bilevel positive airway pressure or continuous positive airway pressure) or invasive respiratory support (mechanical ventilation); (2) MOG or AQP4 antibody positivity with fulfillment of MOGAD and AQP4-NMOSD clinical diagnostic criteria, respectively; and (3) sufficient clinical details. We collected data on demographics, comorbid conditions, indication for and duration of respiratory support, MRI findings, treatments, and outcomes. The races of those with attacks requiring respiratory support were compared to those without such attacks in MOGAD and AQP4-NMOSD. RESULTS: Attacks requiring ventilatory support were similarly rare in patients with MOGAD (8 of 279, 2.9%) and AQP4-NMOSD (11 of 503 [2.2%]) (p = 0.63). The age at attack (median years [range]) (MOGAD 31.5 [5–47] vs AQP4-NMOSD 43 [14–65]; p = 0.01) and percentage of female sex (MOGAD 3 of 8 [38%] vs AQP4-NMOSD 10 of 11 [91%]; p = 0.04) differed. The reasons for ventilation differed between MOGAD (inability to protect airway from seizure, encephalitis or encephalomyelitis with attacks of acute disseminated encephalomyelitis 5 [62.5%] or unilateral cortical encephalitis 3 [37.5%]) and AQP4-NMOSD (inability to protect airway from cervical myelitis 9 [82%], rhombencephalitis 1 [9%], or combinations of both 1 [9%]). Median ventilation duration for MOGAD was 2 days (range 1–7 days) vs 19 days (range 6–330 days) for AQP4-NMOSD (p = 0.01). All patients with MOGAD recovered, but 2 of 11 (18%) patients with AQP4-NMOSD died of the attack. For AQP4-NMOSD, Black race was overrepresented for attacks requiring ventilatory support vs those without these episodes (5 of 11 [45%] vs 88 of 457 [19%]; p = 0.045). DISCUSSION: Ventilatory support is rarely required for MOGAD and AQP4-NMOSD attacks, and the indications differ. Compared to MOGAD, these attacks in AQP4-NMOSD may have higher morbidity and mortality, and those of Black race were more predisposed, which we suspect may relate to socially mediated health inequality. Lippincott Williams & Wilkins 2021-09-28 /pmc/articles/PMC8480400/ /pubmed/34389648 http://dx.doi.org/10.1212/WNL.0000000000012599 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Research Article
Zhao-Fleming, Hannah H.
Valencia Sanchez, Cristina
Sechi, Elia
Inbarasu, Jery
Wijdicks, Eelco F.
Pittock, Sean J.
Chen, John J.
Wingerchuk, Dean M.
Weinshenker, Brian G.
Lopez-Chiriboga, Sebastian
Dubey, Divyanshu
Tillema, Jan-Mendelt
Toledano, Michel
Yadav, Hemang
Flanagan, Eoin P.
CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
title CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
title_full CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
title_fullStr CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
title_full_unstemmed CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
title_short CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
title_sort cns demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480400/
https://www.ncbi.nlm.nih.gov/pubmed/34389648
http://dx.doi.org/10.1212/WNL.0000000000012599
work_keys_str_mv AT zhaofleminghannahh cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT valenciasanchezcristina cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT sechielia cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT inbarasujery cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT wijdickseelcof cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT pittockseanj cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT chenjohnj cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT wingerchukdeanm cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT weinshenkerbriang cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT lopezchiribogasebastian cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT dubeydivyanshu cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT tillemajanmendelt cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT toledanomichel cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT yadavhemang cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies
AT flanaganeoinp cnsdemyelinatingattacksrequiringventilatorysupportwithmyelinoligodendrocyteglycoproteinoraquaporin4antibodies